Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Principal Investigator
Antonio Omuro, MD
Status
Terminated
Date Opened To Accrual
September 07 2011
Date Closed to Accrual
January 15 2016
Date of Study Termination
May 20 2022
Disease Site
Brain [BN]
Other
Phase
II
Developmental Therapeutics
No
Primary Objective
To determine median progression-free survival (PFS) in both arms on an intent-to-treat basis. PFS will be defined as the interval from randomization to progression or death, whichever occurs first.
Data Collection Notice:
Data for this trial is being collected via the NRG/RTOG Data Center.
Patient Population
B-cell non-Hodgkin's lymphoma involving the brain, as demonstrated by contrasted MRI and histologic confirmation by one of the following within 6 weeks prior to registration:
- A positive CSF cytology for lymphoma or a monoclonal lymphocyte population as defined by cell surface markers
- A biopsy of the vitreous or uvea demonstrating non-Hodgkin's lymphoma
- Brain biopsy
Target Accrual
89
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.